Moreno-Luna Laura E, Arrieta Oscar, García-Leiva Jorge, Martínez Braulio, Torre Aldo, Uribe Misael, León-Rodríguez Eucario
Department of Gastroenterology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
BMC Cancer. 2005 Oct 31;5:142. doi: 10.1186/1471-2407-5-142.
Fibrolamellar Carcinoma (FLC), a subtype of hepatocellular carcinoma (HCC), is a rare primary hepatic malignancy. Several aspects of the clinic features and epidemiology of FLC remain unclear because most of the literature on FLC consists of case reports and small cases series with limited information on factors that affect survival.
We did a retrospective analysis of the clinical and histological characteristics of FLC. We also determined the rate of cellular proliferation in biopsies of these tumors. We assessed whether these variables were associated with survival.
We found 15 patients with FLC out of 174 patients with HCC (8.6%). Between patients with these neoplasms, we found statistically significant survival, age at onset, level of alpha fetoprotein, and an earlier stage of the disease. The 1, 3 and 5 year survival in patients with FLC was of 66, 40 and 26% respectively. The factors associated with a higher survival in patients with FLC were age more than 23 years, feasibility of surgical resection, free surgical borders, absence of thrombosis or invasion to hepatic vessels and the absence of alterations in liver enzymes. The size of the tumor, gender, cellular proliferation and atypia did not affect the prognosis.
We concluded that FLC patients diagnosed before 23 years of age have worse prognosis than those diagnosed after age 23. Other factors associated with worse prognosis in this study are: lack of surgical treatment, presence of positive surgical margins, vascular invasion, and altered hepatic enzymes.
纤维板层癌(FLC)是肝细胞癌(HCC)的一种亚型,是一种罕见的原发性肝脏恶性肿瘤。FLC的临床特征和流行病学的几个方面仍不清楚,因为大多数关于FLC的文献都是病例报告和小病例系列,关于影响生存的因素的信息有限。
我们对FLC的临床和组织学特征进行了回顾性分析。我们还确定了这些肿瘤活检中的细胞增殖率。我们评估了这些变量是否与生存相关。
在174例HCC患者中,我们发现了15例FLC患者(8.6%)。在这些肿瘤患者之间,我们发现生存、发病年龄、甲胎蛋白水平和疾病早期在统计学上有显著差异。FLC患者的1年、3年和5年生存率分别为66%、40%和26%。与FLC患者较高生存率相关的因素是年龄超过23岁、手术切除的可行性、手术切缘阴性、无肝血管血栓形成或侵犯以及肝酶无改变。肿瘤大小、性别、细胞增殖和异型性不影响预后。
我们得出结论,23岁之前诊断的FLC患者的预后比23岁之后诊断的患者更差。本研究中与较差预后相关的其他因素是:缺乏手术治疗、手术切缘阳性、血管侵犯和肝酶改变。